Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gherardo Mazziotti

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
Pituitary|November 8, 2007
The long-term cardiovascular outcome of different GH-lowering treatments in acromegalyLaura De Marinis, Antonio Bianchi, Gherardo Mazziotti, et al.
Clinical Endocrinology|February 19, 2002
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegalyGiovanni Amato, Gherardo Mazziotti, Mario Rotondi, et al.
Biomedicines|March 29, 2023
ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and ShadowMaria Francesca Birtolo, Simone Antonini, Andrea Saladino, et al.
EJNMMI Research|June 1, 2023
The complementary role of PSMA expression and [<sup>18</sup>F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncologyMartina Sollini, Margarita Kirienko, Luca di Tommaso, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissueFrancesca Sorvillo, Gherardo Mazziotti, Antonella Carbone, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 18, 2024
From Adenoma to Carcinoma: the Unexpected Evolution of an Apparently Stable Adrenal LesionGiacomo Cristofolini, Giulia Maida, Simona Jaafar, et al.
Journal of Clinical Medicine|March 28, 2026
Monocyte-to-Lymphocyte Ratio as New Prognostic Factor in Patients with Medullary Thyroid CarcinomaLuca Canali, Francesca Gaino, Claudia Valenziano, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 18, 2024
Late-onset Schmidt's Syndrome Presenting with Severe Hyponatremia: A Case ReportStella Pigni, Giacomo Cristofolini, Simona Jaafar, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 29, 2026
Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage studyJacopo Ciaffi, Barbara Bordini, Monica Cosentino, et al.
Clinical Endocrinology|February 13, 2003
Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosisFrancesca Sorvillo, Gherardo Mazziotti, Antonella Carbone, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
Pituitary|November 8, 2007
The long-term cardiovascular outcome of different GH-lowering treatments in acromegalyLaura De Marinis, Antonio Bianchi, Gherardo Mazziotti, et al.
Clinical Endocrinology|February 19, 2002
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegalyGiovanni Amato, Gherardo Mazziotti, Mario Rotondi, et al.
Biomedicines|March 29, 2023
ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and ShadowMaria Francesca Birtolo, Simone Antonini, Andrea Saladino, et al.
EJNMMI Research|June 1, 2023
The complementary role of PSMA expression and [<sup>18</sup>F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncologyMartina Sollini, Margarita Kirienko, Luca di Tommaso, et al.
The Journal of Clinical Endocrinology and Metabolism|October 15, 2003
Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissueFrancesca Sorvillo, Gherardo Mazziotti, Antonella Carbone, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 18, 2024
From Adenoma to Carcinoma: the Unexpected Evolution of an Apparently Stable Adrenal LesionGiacomo Cristofolini, Giulia Maida, Simona Jaafar, et al.
Journal of Clinical Medicine|March 28, 2026
Monocyte-to-Lymphocyte Ratio as New Prognostic Factor in Patients with Medullary Thyroid CarcinomaLuca Canali, Francesca Gaino, Claudia Valenziano, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 18, 2024
Late-onset Schmidt's Syndrome Presenting with Severe Hyponatremia: A Case ReportStella Pigni, Giacomo Cristofolini, Simona Jaafar, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 29, 2026
Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage studyJacopo Ciaffi, Barbara Bordini, Monica Cosentino, et al.
Clinical Endocrinology|February 13, 2003
Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosisFrancesca Sorvillo, Gherardo Mazziotti, Antonella Carbone, et al.
Pageof 16